By Dan Levine June 14, 2022 (Reuters) – U.S. health regulators rejected a request to remove popular anti-baldness pill Propecia and its generic versions from the market, but for the first time required patient notification about reports of suicidal behavior in men taking the drug. The U.S. Food and Drug Administration has previously approved revised Propecia labels...